Research indicates that geographic-related disparities with regard to patient access to gynecologic oncologists occurs in an estimated 35% of ovarian cancer patients. Moreover, this disparity becomes more evident as advances in the treatment of ovarian cancer continues to expand, especially in regard to maintenance therapy (e.g., poly [ADP-ribose] polymerase [PARP] inhibitors). As a result, health experts indicate that it is essential for gynecologists who are most likely to be caregivers of these patients over the span of their lives, have a thorough understanding of the management of these patients. 

In the study, Vanessa Carranza, PharmD, and colleagues from Creative Educational Concepts Oncology, Lexington, Kentucky created an educational initiative presented at four American College of Obstetricians and Gynecologists District Meetings, focusing on obstetricians, gynecologists, and other health professionals. 

Education initiatives focused on PARP inhibitors in ovarian cancer, identification of those eligible for genetic testing and counseling, and strategies to enhance patient outcomes. Evaluations were compiled from attendees attending the District Meetings to evaluate impact on practice, expanded competency, and intent to make a change in practice. 

This was objectively evaluated via analyzing pre-test, post-test, and follow-up survey data (sent 4-6 weeks post-activity). Chi-square analysis was conducted with a priori significance set at 0.05. 

The authors noted that a total of 183 clinicians were educated, practicing in academic settings (44%), community hospital settings (24%), private practice (25%), and government (7%). Attendees were asked case questions at baseline, directly after the activity, and 4-6 weeks after the activity to evaluate knowledge about the DNA damage response pathway, genetic testing guidelines, and management of therapy toxicities.

Understanding improved from pre- to post-test and from pre-test to follow-up for all topics, with the greatest increase in the management of adverse events (41% increase from pre- to post-test; 50% increase from pre-test to follow-up; P< 0.01). 

Moreover, there was a 22% and 24% boost in confidence in recognizing patients eligible for germline genetic testing and in identifying toxicities with PARP inhibitors from pre-test to six-week follow-up, respectively. Also, 60% of participants acknowledged that there was a lack of patient education regarding the significance of genetic testing and counseling. At follow-up, 100% stated that they had informed patients about genetic testing and counseling, emphasizing the value of educating gynecologists on this topic. 

The authors concluded, “Attendees of this educational initiative were eager to take back the knowledge learned to their clinical practices. While there was a measurable increase in knowledge with regard to different ovarian cancer related topics, educational gaps remain. Collectively, this particular audience stated that they care for > 1,000 ovarian cancer patients, elucidating the need for OB/GYNs to feel more comfortable regarding PARP inhibitor toxicities, as they become more prevalent in practice.”

Reference

Carranza V, Taylor B, Gitzinger S, et al. The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients. Abstract presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago, IL, and virtual. Abstract e23003.